Showing 2371-2380 of 7605 results for "".
Physician Spotlight: Desiree Ratner, MD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-desiree-ratner-md/20505/Winning the war on non-melanoma skin cancer.Physician Spotlight: J. Matthew Knight, MD, FAAD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-j-matthew-knight-md-faad/20561/Dermatologists must act now to extinguish burnout or risk dire consequences.Are These Three Weaknesses Lurking In Your LLC Or FLP?
https://practicaldermatology.com/topics/practice-management/are-these-three-weaknesses-lurking-in-your-llc-or-flp/21075/LLCs and FLPs are only as strong or weak as their operating documents and ongoing compliance management.Panel Supports ATX-101; Melanoma Metastasis Test
https://practicaldermatology.com/topics/practice-management/dermwiretv-panel-supports-atx-101-melanoma-metastasis-test/18959/An FDA Advisory Panel Backs Kythera's ATX-101 for (Submental Fullness) or Double Chin, and a new genetic analysis may enhance SLN Biopsy findings to identify melanoma metastasis.Plus, Dan Siegel, MD, Darrell Rigel, MD, and Neal Bhatia, MD discuss the AAD's proposed dues increase and @NewDermMD launcWhat Will Be Our Legacy?
https://practicaldermatology.com/topics/practice-management/what-will-be-our-legacy/21434/Practical Dermatology® Magazine Welcomes Neal Bhatia, MD, FAAD as Co-Chief Medical EditorOn Dosage and Diet: Isotretinoin 101
https://practicaldermatology.com/topics/general-topics/on-dosage-and-diet-isotretinoin-101/21445/Isotretinoin is one of the most essential agents in the treatment of acne, but dietary and dosage considerations must be made to maximize efficacy. Author:Joshua Zeichner, MDFDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
https://practicaldermatology.com/series/dermwire-tv/fda-approves-eli-lillys-ad-drug-ebglyss-lebrikizumab/28645/In this week's DermwireTV, Andrew F. Alexis, MD, Professor of Clinical Dermatology at Weill Cornell Medical College, discusses the newly approved AD drug lebrikizumab; LEO Pharma announces two major regulatory milestones for its chronic hand eczema (CHE) treatment; and the CMO of Arcutis BioteherapuDiverse by Design: The Unique Molecular Footprints of IL-23 Biologics in Psoriasis
https://practicaldermatology.com/issues/april-2024/il23_biologics_in_psoriasis/24457/Christopher Bunick, MD, PhD, discusses a study that explores the structural basis of IL-23 targeted biologic therapies for psoriasis. By mapping the binding sites of these therapies on the IL-23 molecule and correlating molecular properties with clinical efficacy, the study offers insights into whyImproving Staff Retention Through Performance Management
https://practicaldermatology.com/topics/practice-management/improving-staff-retention-through-performance-management/23920/A thoughtful and structured review process opens the lines of communication.Exploring Patient-Reported Outcomes Measures in Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/exploring-patient-reported-outcomes-measures-in-atopic-dermatitis/23886/Patient-reported outcomes may solve some of the challenges with measuring the physical and psychosocial manifestations.